Nasdaq · Biotech stocks database
BOLD (Boundless Bio Inc.) stock: $2.46, $56.9M market cap, $72.6M cash, -$15.7M EV, $71.8M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We expect to have initial proof-of-concept safety and efficacy clinical data from the KOMODO-1 trial of BBI-940 within our existing cash runway timeline discussed below. We have been investigating BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 designed to target replication stress in oncogene amplified cancers, and BBI-825, a novel oral, selective inhibitor of ribonucleotide reductase, in the clinic in the POTENTIATE trial and the STARMAP trial.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $72.6M |
|---|---|
| Debt | $0.0M |
| Net cash | $72.6M |
| Enterprise value | -$15.7M |
| Basic shares | 22.7M shares |
| Fully diluted shares | 29.2M shares |
| Fully diluted market cap | $71.8M |
| Cash per share | $3.19 |
| Quarterly burn | $21.0M |
| Cash runway | 3.5 quarters |
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Cap table as of 2026-08-05.
Loading BOLD daily closes…